Summary
Definition
History and exam
Key diagnostic factors
- amenorrhea or oligomenorrhea
- infertility
- galactorrhea
- loss of sexual desire (libido)
- erectile dysfunction
- visual deterioration
Other diagnostic factors
- osteoporosis
Risk factors
- female sex, 20-50 years of age
- genetic predisposition
Diagnostic tests
1st tests to order
- serum prolactin
- pituitary MRI
- computerized visual field exam
Treatment algorithm
premenopausal women
postmenopausal women
men: microadenoma or macroadenoma
refractory or aggressive prolactinoma
Contributors
Authors
Niamh Martin, MB ChB, PhD, FRCP
Professor of Endocrinology
Imperial Centre for Endocrinology
Department of Metabolism, Digestion and Reproduction
Imperial College London
London
UK
Disclosures
NM declares that she has no competing interests.
Acknowledgements
Professor Niamh Martin would like to gratefully acknowledge Dr Ilan Shimon, the previous contributor to this topic.
Disclosures
IS receives consultancy and lecturing fees from Pfizer, Israel, and is an author of a number of references cited in this topic.
Peer reviewers
Mark Molitch, MD
Professor
Division of Endocrinology
Northwestern University Feinberg School of Medicine
Chicago, IL
Disclosures
MM is an author of a number of references cited in this topic.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Fleseriu M, Varlamov EV, Akirov A, et al. Prolactin-secreting adenomas: pathogenesis, diagnosis, and management. Lancet Diabetes Endocrinol. 2025 Oct;13(10):874-90. Abstract
Auriemma RS, Pirchio R, Pivonello C, et al. Approach to the patient with prolactinoma. J Clin Endocrinol Metab. 2023 Aug 18;108(9):2400-23.Full text Abstract
Petersenn S, Fleseriu M, Casanueva FF, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international consensus statement. Nat Rev Endocrinol. 2023 Dec;19(12):722-40.Full text Abstract
Raverot G, Burman P, Abreu AP, et al. Revised European Society of Endocrinology clinical practice guideline for the management of aggressive pituitary tumours and pituitary carcinomas. Eur J Endocrinol. 2025 May 30;192(6):R45-78.Full text Abstract
Luger A, Broersen LHA, Biermasz NR, et al. ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy. Eur J Endocrinol. 2021 Aug 23;185(3):G1-33.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.

Differentials
- Nonfunctioning pituitary macroadenomas
- Drug-induced hyperprolactinemia
- Primary hypothyroidism
More DifferentialsGuidelines
- Revised European Society of Endocrinology clinical practice guideline for the management of aggressive pituitary tumours and pituitary carcinomas
- ESE clinical practice guideline on functioning and nonfunctioning pituitary adenomas in pregnancy
More GuidelinesLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer